Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 125

Sort by

Sort Order Select

Journal Articles

Norsworthy KJ, Bird ST, Avagyan A, et al. Second cancers in adults with acute promyelocytic leukemia (APL) treated with or without arsenic trioxide (ATO): a SEER-Medicare analysis [abstract]. Blood. 2019;134(suppl 1). Abstract 3497.

Blood (2020) 135 (23): 2111.

https://doi.org/10.1182/blood.2020006455

Published: 2020

Journal Articles

Health Insurance Status Impacts Rates of Overall Survival in Philadelphia-Positive Acute Lymphoblastic Leukemia

Jeremy Chang, MD, Sherry Zhang, MD, Mojtaba Akhtari, MD

Blood (2019) 134 (Supplement_1): 2581.

https://doi.org/10.1182/blood-2019-123738

Published: 2019

Journal Articles

Epidemiology and Survival Outcomes in Elderly Acute Myeloid Leukemia Patients: An NCDB Study

Hussain I Rangoonwala, MBBS, Jonathan Gootee, MD, Peter T. Silberstein, MD

Blood (2019) 134 (Supplement_1): 3840.

https://doi.org/10.1182/blood-2019-131233

Published: 2019

Journal Articles

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Erlene K. Seymour, MD, Lucius Daniel, Eva Pointer, MS, Stephen T. Smith, Charles A. Schiffer, MD

Blood (2019) 134 (Supplement_1): 64.

https://doi.org/10.1182/blood-2019-128905

Published: 2019

Journal Articles

Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy

Shaum M Kabadi, PhD MPH, Ravi K Goyal, MS, Saurabh P Nagar, MS, Keith L Davis, MA, Hannah Le, PharmD, MPH, Xianglin L Du, MB, MS, PhD, Preetesh Jain, MBBS,MDDM,PhD, Michael L. Wang, MD, Jorge Enrique Romaguera, MD, James A Kaye, MD

Blood (2019) 134 (Supplement_1): 63.

https://doi.org/10.1182/blood-2019-122841

Published: 2019

Journal Articles

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma

Anne Shah, MS, Allison Petrilla, MPH, Mayvis Rebeira, PhD, Joseph Feliciano, PharmD, Thomas W. LeBlanc, MDMA,MHS, Julie Lisano, PharmD

Blood (2019) 134 (Supplement_1): 3492.

https://doi.org/10.1182/blood-2019-130973

Published: 2019

Journal Articles

Sociodemographic and Clinical Characteristics Associated with Patient's Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on Outcomes

Vivek Kumar, MD, M.B.,B.S., Mays F Abdulazeez, MBBS, Srilekha Bodepudi, Suman Biswas, Vivek Roy, MD, Taimur Sher, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 3494.

https://doi.org/10.1182/blood-2019-125888

Published: 2019

Journal Articles

Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US

Jessica J Jalbert, PhD, Umesh Chaudhari, MD, Haixin Zhang, MSc, Jonathan Weyne, MD, Jamile M. Shammo, MD

Blood (2019) 134 (Supplement_1): 3407.

https://doi.org/10.1182/blood-2019-125867

Published: 2019

Journal Articles

Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis

Kelly J. Norsworthy, MD, Steven T. Bird, PhD PharmD, MS, Armen Avagyan, MS, Yuchen Li, MS, Sandia Akhtar, BS, Jiemin Liao, MA, Michael Wernecke, BA, Albert B. Deisseroth, MD PhD, Meredith Chuk, MD, Thomas E. MaCurdy, PhD, Richard Swain, PhD, Jeffrey A. Kelman, MD MMSc, Ann T. Farrell, MD, Richard Pazdur, MD, Gideon Blumenthal, MD, David J. Graham, MD MPH

Blood (2019) 134 (Supplement_1): 3497.

https://doi.org/10.1182/blood-2019-130295

Published: 2019

Journal Articles

Safety and Effectiveness of Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Venous Thrombosis: A SEER-Medicare-Linked Data Analysis

Christine G. Kohn, PharmD, Gary H. Lyman, MD MPH, Nicole M. Kuderer, Thomas J. Bunz, PharmD, PhD, Craig I. Coleman, PharmD

Blood (2019) 134 (Supplement_1): 3673.

https://doi.org/10.1182/blood-2019-128581

Published: 2019

Journal Articles

Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Eytan M. Stein, MD, Dominick Latremouille-Viau, George J Joseph, Sherry Shi, Annie Guerin, MSc, Eric Q Wu, Gaetano Bonifacio, Xiting Cao

Blood (2019) 134 (Supplement_1): 3495.

https://doi.org/10.1182/blood-2019-124878

Published: 2019

Journal Articles

Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML

Ivy Abraham, MD, Garth Rauscher, PhD MPH, Anand Ashwin Patel, MD, Wendy Stock, MD, Maryam Zia, MD, Sushma Bharadwaj, MD, Koosha Paydary, MD, Maria Acevedo-Mendez, John P Galvin, MDMS,MPH, William Pearse, MD, Jessica K. Altman, John G. Quigley, Priya Rajakumar, MD, Melissa L. Larson, MD, Irum Khan, MD

Blood (2019) 134 (Supplement_1): 3413.

https://doi.org/10.1182/blood-2019-124974

Published: 2019

Journal Articles

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Karl M. Kilgore, PhD, Iman Mohammadi, PhD, Amy Schroeder, BPharm, Christie Teigland, PhD, Anna Purdum, PharmD,MS, Gunjan L. Shah, MD

Blood (2019) 134 (Supplement_1): 793.

https://doi.org/10.1182/blood-2019-124364

Published: 2019

Journal Articles

Overall Survival, Adverse Events, and Economic Burden in Medicare Patients with Chronic Lymphocytic Leukemia Receiving Cancer-Directed Therapy

Ravi K Goyal, MS, Saurabh P Nagar, MS, Shaum M Kabadi, PhD MPH, Keith L Davis, MA, Hannah Le, PharmD, MPH, James A Kaye, MD

Blood (2019) 134 (Supplement_1): 796.

https://doi.org/10.1182/blood-2019-122842

Published: 2019

Journal Articles

Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea

Rong Wang, PhD, Rory M Shallis, MD, Scott F. Huntington, MD MPH, Amer M. Zeidan, MBBS, MHS, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD, Nikolai A. Podoltsev, MD PhD

Blood (2019) 134 (Supplement_1): 330.

https://doi.org/10.1182/blood-2019-127568

Published: 2019

Journal Articles

Adoption of Prophylaxis in the United States in the Era of Extended Half-Life Factor Concentrates

Lynn M. Malec, MD, Gilbert C. White, MD, Stacy E. Croteau, MD, Dunlei Cheng, PhD, Margaret V. Ragni, MD MPH

Blood (2018) 132 (Supplement 1): 2467.

https://doi.org/10.1182/blood-2018-99-115231

Published: 2018

Journal Articles

Influence of Pomalidomide and Lenalidomide on Total Cost of Care for Medicare Beneficiaries with Multiple Myeloma Under the Oncology Care Model (OCM)

Haley Hines Theroux, Luis M Isola, MD, Mark Liu, Alaysia Williams, MHA

Blood (2018) 132 (Supplement 1): 2252.

https://doi.org/10.1182/blood-2018-99-116657

Published: 2018

Journal Articles

Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings

Neil Dunavin, MD, Lih-Wen Mau, PhD MPH, Christa Lea Meyer, MS, Clint Divine, Al-Ola Abdallah, MD, Susan Leppke, MPH, Anita D'Souza, MBBS, Ellen Denzen, MS, Wael Saber, MD MS, Linda J. Burns, MD, Siddhartha Ganguly, MD

Blood (2018) 132 (Supplement 1): 832.

https://doi.org/10.1182/blood-2018-99-118423

Published: 2018

Journal Articles

End-of-Life Care Quality Outcomes Among Medicare Beneficiaries with Hematologic Malignancies

Pamela C Egan, MD, Thomas W. LeBlanc, MD MA, Adam J Olszewski, MD

Blood (2018) 132 (Supplement 1): 829.

https://doi.org/10.1182/blood-2018-99-112692

Published: 2018

Journal Articles

Real-World Treatment Patterns and Comparative Effectiveness Among a Population of Elderly Patients with Acute Myeloid Leukemia (AML)

Bruno C. Medeiros, MD, Sacha Satram-Hoang, Faiyaz Momin, Monika Parisi

Blood (2018) 132 (Supplement 1): 835.

https://doi.org/10.1182/blood-2018-99-111267

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Norsworthy KJ, Bird ST, Avagyan A, et al. Second cancers in adults with acute promyelocytic leukemia (APL) treated with or without arsenic trioxide (ATO): a SEER-Medicare analysis [abstract]. Blood. 2019;134(suppl 1). Abstract 3497.

Health Insurance Status Impacts Rates of Overall Survival in Philadelphia-Positive Acute Lymphoblastic Leukemia

Epidemiology and Survival Outcomes in Elderly Acute Myeloid Leukemia Patients: An NCDB Study

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Overall Survival, Adverse Events, and Economic Burden in Medicare-Insured Patients with Mantle Cell Lymphoma Receiving Cancer-Directed Therapy

Real-World Treatment Patterns and Overall Survival Among Medicare Fee-for-Service Beneficiaries Newly Diagnosed with Peripheral T-Cell Lymphoma

Sociodemographic and Clinical Characteristics Associated with Patient's Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on Outcomes

Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US

Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis

Safety and Effectiveness of Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Venous Thrombosis: A SEER-Medicare-Linked Data Analysis

Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML

Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Overall Survival, Adverse Events, and Economic Burden in Medicare Patients with Chronic Lymphocytic Leukemia Receiving Cancer-Directed Therapy

Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea

Adoption of Prophylaxis in the United States in the Era of Extended Half-Life Factor Concentrates

Influence of Pomalidomide and Lenalidomide on Total Cost of Care for Medicare Beneficiaries with Multiple Myeloma Under the Oncology Care Model (OCM)

Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings

End-of-Life Care Quality Outcomes Among Medicare Beneficiaries with Hematologic Malignancies

Real-World Treatment Patterns and Comparative Effectiveness Among a Population of Elderly Patients with Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only